ImmunoGen

NASDAQ: IMGN
$3.52
+$0.13 (+3.8%)
Real time price as of April 8, 2020 12:02 pm EDT
ImmunoGen shares jumped on Tuesday after the FDA advised that a new single-arm study in platinum-resistant ovarian cancer could support accelerated approval.
Chris Lange
ImmunoGen shares dropped on Monday after the firm released data from its late-stage ovarian cancer study at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.
Chris Lange
The top analyst upgrades, downgrades and initiations seen on Tuesday included Boeing, Booking, Camping World, Domino's Pizza, iRobot, MetLife, Neogen, Southern Copper, Vertex Pharmaceuticals and...
Jon C. Ogg
The top analyst upgrades, downgrades and initiations seen on Monday included Alector, Bed Bath & Beyond, Dillard's, Foot Locker, Hasbro, Kraft Heinz, Vale, Xilinx and Zoetis.
Jon C. Ogg
ImmunoGen shares were halved on Friday after the firm reported late-stage results from its ovarian cancer study.
Chris Lange
Here are five biotech stocks that are rated Buy by the Jefferies analysts, are trading under the $10 level and could provide investors with some solid upside potential.
Lee Jackson
ImmunoGen shares benefited after the company presented data for its latest assessment of mirvetuximab soravtansine at the Society of Gynecologic Oncology annual meeting.
Jon C. Ogg
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates for the rest of March.
Chris Lange
24/7 Wall St. includes a calendar of a few of the biggest companies expecting clinical trial and FDA updates in the month of March.
Chris Lange
The top analyst upgrades, downgrades and other research calls from Wednesday include AK Steel, Apple, Biogen, Electronic Arts, FitBit, Foot Locker, McDonald's and Pfizer.
Jon C. Ogg
Cancer drug developer ImmunoGen posted sharply lower profits and revenues than analysts were expecting. The stock is taking a beating as a result.
Paul Ausick
ImmunoGen saw its shares make a sharp turn downward on Thursday morning after the stock has seen an incredible year of trading so far.
Chris Lange
ImmunoGen announced this week that it has decided to partner with Jazz Pharmaceuticals, and investors have pushed Immunogen shares to a new 52-week high.
Trey Thoelcke
ImmunoGen has decided to partner with Jazz Pharmaceuticals for the development and commercialization of two early-stage, hematology-related antibody-drug conjugate programs.
Chris Lange
The top analyst upgrades, downgrades and other research calls from Thursday include AutoZone, O'Reilly Automotive, Immunogen, Medtronic, Nike, OncoSec Medical and Schlumberger.
Jon C. Ogg